This question comes up in almost every early conversation about binder discovery programs: should we use a library, or should we try computational design? The framing is wrong. These are not competing methods. They solve different problems. Choosing between them depends on your target, your timeline, and what you already have.
Library screening: mature, scalable, and sequence-space limited
Library-based binder discovery (phage display, yeast display, ribosome display) works by sampling diversity within a defined scaffold and selecting against a target. The approach is well-validated across decades of antibody and alternative scaffold discovery programs. Its advantages are well understood:
- Proven hit rates on soluble extracellular targets with accessible epitopes
- Straightforward path from hit to lead: affinity maturation, selectivity profiling, expression characterization
- Regulatory precedent for antibody scaffolds in clinical programs
- Predictable cost structure
The limitation is equally well understood: you can only find what your library contains. Library diversity is sampled from a finite, pre-defined sequence space, typically randomization within a known scaffold framework at positions selected for tolerance to variation. For a target with a well-characterized epitope and a precedented binding geometry, this is sufficient. For targets where the right answer is geometrically outside the library’s distribution, it is not.
De novo design: strongest where libraries fail
Diffusion-based de novo design (RFdiffusion, BindCraft, Boltzgen) generates binder candidates computationally, guided by the three-dimensional structure of the target. The candidates are not derived from any prior scaffold. They are generated from scratch, conditioned on the epitope you specify.
This is strongest in the following situations:
Novel targets with no existing binder scaffold. If you are working on a target class where no antibody, nanobody, or alternative scaffold has been validated, library screening requires building (and validating) a library specifically for that target type. De novo design sidesteps the scaffold selection problem.
Challenging epitopes. Concave binding surfaces, protein-protein interface grooves, receptor pockets, and enzyme active sites are geometrically constrained in ways that conventional antibody frameworks do not naturally engage. Miniprotein and custom scaffold design allows you to specify the approach geometry directly.
Cases where immunization is not practical or fast enough. For research tool binders, diagnostic reagents, or programs where the timeline does not accommodate an immunization campaign, de novo design can start as soon as you have a target structure.
Targets where multiple prior library campaigns have failed. If three library campaigns have produced no confirmed binders, the problem is likely the scaffold’s inability to access the relevant epitope, not a problem that another library will solve.
Identify epitopes on your own target. Epitope Scout scores and ranks surface patches on any PDB structure. Free to use.
Decision framework
| Situation | Preferred approach |
|---|---|
| Target has accessible epitope, precedented scaffold geometry | Library screening |
| Target is a novel protein class with no prior binders | De novo design |
| Timeline: immunization is an option | Library or hybridoma |
| Timeline: 6-8 weeks to first confirmed hits | De novo design |
| Epitope is a flat or accessible extracellular domain | Library screening |
| Epitope is a concave pocket, PPI interface, or recessed groove | De novo design |
| Prior library campaigns have failed | De novo design |
| Binder needs to be a full-length IgG | Library screening |
| Binder format is flexible (nanobody, miniprotein acceptable) | De novo design |
| Need high diversity around confirmed lead | Affinity maturation (post-screen) |
The most powerful programs couple both
The distinction between de novo design and library screening is sharpest at the start of a discovery program, when no binder exists. Once you have a confirmed hit, even a weak one, the problem changes. Affinity maturation, stability optimization, and selectivity profiling are all better addressed by library methods (deep mutational scanning, focused diversity) than by returning to de novo generation.
The strongest integrated approach is: de novo design to identify a starting scaffold that engages the target, followed by display-based affinity maturation to optimize the lead. Ranomics’ Sprint program uses this structure: the computational campaign identifies starting binders, and the display screen simultaneously validates them and provides the selection pressure needed to enrich higher-affinity variants.
De novo design has collapsed the front of the discovery timeline. Experimental validation and optimization are still rate-limiting, and still require the same rigorous display and sequencing infrastructure that library campaigns depend on.
Talk to us about which approach fits your target: Contact Ranomics
Related Ranomics services
- Biotechnology services: Combined design + library programs matched to the target class.
- AI Binder Sprint: When de novo design is the right call: our flagship program.